Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy.
Niels WestergaardLise TarnowCharlotte VermehrenPublished in: Metabolites (2021)
The use of clopidogrel and PPIs either alone or in combination is quite widespread, in particular among the elderly and persons with diabetes. This further supports the emerging need of accessing and accounting for not only DDI but also for applying PGx-guided drug therapy in clinical decision making for antiplatelet therapy with clopidogrel having a particular focus on persons with diabetes and the elderly.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- type diabetes
- cardiovascular disease
- glycemic control
- decision making
- coronary artery disease
- middle aged
- emergency department
- community dwelling
- stem cells
- insulin resistance
- drug induced
- risk assessment
- bone marrow
- metabolic syndrome
- weight loss
- skeletal muscle